Jeremy S Abramson (Jeremy Abramson)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 65

Top Topics

Tyrosine Kinase

Hodgkin Lymphoma

Prognostic Factors

Top Venues

Leukemia & lymphoma

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Inhye E Ahn, Danielle M Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A Walker, Robert Black, Josie Montegaard, Alvaro J Alencar, Leyla Shune, Mohammad Omaira, Caron A Jacobson, Philippe Armand, Samuel Y Ng, Jennifer L Crombie, David C Fisher, Ann Steward LaCasce, Jon E Arnason, Ephraim P Hochberg, Ronald W Takvorian, Jeremy S Abramson, Jennifer R Brown, Matthew S Davids
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood advances (2024)
Judith Trotman, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine (2024)
Matthew M Lei, Mark N Sorial, Uvette Lou, Michelle Yu, Andrea Medrano, Josie Germain Ford, Ronald A Nemec, Jeremy S Abramson, Jacob D Soumerai
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Leukemia & lymphoma 65 (5) (2024)
Judith Trotman, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine 30 (8) (2024)
Judith Trotman, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine (2024)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances 8 (2) (2024)
Matthew M Lei, Mark N Sorial, Uvette Lou, Michelle Yu, Andrea Medrano, Josie Germain Ford, Ronald A Nemec, Jeremy S Abramson, Jacob D Soumerai
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Leukemia & lymphoma (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia R Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina M Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Naomi Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL. Blood (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood 143 (16) (2024)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances 8 (2) (2024)
Inhye E Ahn, Danielle M Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A Walker, Robert Black, Josie Montegaard, Alvaro J Alencar, Leyla Shune, Mohammad Omaira, Caron A Jacobson, Philippe Armand, Samuel Y Ng, Jennifer Crombie, David C Fisher, Ann Steward LaCasce, Jon Arnason, Ephraim P Hochberg, Ronald W Takvorian, Jeremy S Abramson, Jennifer R Brown, Matthew S Davids
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood advances 8 (4) (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin M Parsons, Paolo Caimi, Ian W Flinn, Alex F Herrera, Jeff P Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Blood (2024)
Judith Trotman, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine 30 (8) (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood 143 (16) (2024)
Judith Trotman, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood 143 (16) (2024)
Inhye E Ahn, Danielle M Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A Walker, Robert Black, Josie Montegaard, Alvaro J Alencar, Leyla Shune, Mohammad Omaira, Caron A Jacobson, Philippe Armand, Samuel Y Ng, Jennifer Crombie, David C Fisher, Ann Steward LaCasce, Jon Arnason, Ephraim P Hochberg, Ronald W Takvorian, Jeremy S Abramson, Jennifer R Brown, Matthew S Davids
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood advances 8 (4) (2024)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances 8 (2) (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia R Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina M Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Naomi Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL. Blood (2024)
Judith Trotman, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine (2024)
Matthew M Lei, Mark N Sorial, Uvette Lou, Michelle Yu, Andrea Medrano, Josie Germain Ford, Ronald A Nemec, Jeremy S Abramson, Jacob D Soumerai
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Leukemia & lymphoma 65 (5) (2024)
Judith Trotman, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine (2024)
Julie Erika Haydu, Jeremy S Abramson
The Rules of T-cell Engagement: Current State of CAR T-cells and Bispecific Antibodies in B-cell Lymphomas. Blood advances (2024)
Matthew M Lei, Mark N Sorial, Uvette Lou, Michelle Yu, Andrea Medrano, Josie Germain Ford, Ronald A Nemec, Jeremy S Abramson, Jacob D Soumerai
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Leukemia & lymphoma 65 (5) (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin Parsons, Paolo F Caimi, Ian W Flinn, Alex F Herrera, Jeffrey Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 143 (16) (2024)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances 8 (2) (2024)
Judith Trotman, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine 30 (8) (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin M Parsons, Paolo Caimi, Ian W Flinn, Alex F Herrera, Jeff P Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Blood (2024)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, Brian L Link, Bayard L Powell, Christopher Melani, Andrea Nicole Lucas, Seth M Steinberg, Jonathan W Friedberg, Brad S Kahl, Richard F Little, Nancy L Bartlett, Ariela Noy, Wyndham H Wilson, Mark J Roschewski
Prognostic Factors for Adult Burkitt Lymphoma Patients Treated with Dose-Adjusted EPOCH-R. Blood advances (2023)
David A Qualls, Nicholas Lambert, Paolo F Caimi, Mwanasha H Merrill, Priyanka Pullarkat, Richard C Godby, David A Bond, Graham T Wehmeyer, Jason T Romancik, Behzad Amoozgar, Lori A Leslie, Loretta J Nastoupil, Jennifer L Crombie, Jeremy S Abramson, Arushi Khurana, Grzegorz S Nowakowski, Kami J Maddocks, Sarah C Rutherford, Brad S Kahl, Michelle Okwali, Michael J Buege, Venkatraman E Seshan, Connie Lee Batlevi, Gilles Andre Salles
Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood (2023)
Michael L Wang, Tanya Siddiqi, Leo I Gordon, Manali Kamdar, Matthew Lunning, Alexandre V Hirayama, Jeremy S Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R Solomon, Ana Kostic, Christine Dehner, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Laurie Eliason, Maria Lia Palomba
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics (2023)
Jeremy S Abramson
A new CAR takes a test drive in DLBCL. Blood 141 (20) (2023)
Jee H Choe, Tianzhou Yu, Jeremy S Abramson, Mohamed Abou-El-Enein
Cost-Effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood advances (2023)
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael L Wang, Jon E Arnason, Enkhtsetseg Purev, David G Maloney, Charalambos Babis Andreadis, Alison Sehgal, Scott R Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood (2023)
Robert A Redd, Josie Ford, Matthew M Lei, Jeremy S Abramson, Jacob D Soumerai
Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes. Leukemia & lymphoma (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
Reem Karmali, Jeremy S Abramson, Deborah M Stephens, Jeffrey A Barnes, Jane N Winter, Shuo Ma, Juehua Gao, Jason Kaplan, Adam M Petrich, Xinlei Mi, Ephraim P Hochberg, Ronald W Takvorian, Valerie Nelson, Leo I Gordon, Barbara Pro
Ibrutinib Maintenance Following Frontline Treatment in Patients with Mantle Cell Lymphoma. Blood advances (2023)
Jeremy S Abramson, Scott R Solomon, Jon E Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim G N J Mutsaers, Francisco J Hernandez-Ilizaliturri, Koji Izutsu, Judith Trotman, Matthew A Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood (2022)
Jeremy S Abramson, Patrick B Johnston, Manali Kamdar, Sami Ibrahimi, Koji Izutsu, Jon Arnason, Bertram Glass, Pim Mutsaers, Matthew Lunning, Julia Braverman, Fei Fei Liu, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Shien Guo, Ling Shi, Scott R Solomon
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood advances 6 (23) (2022)
Ken H H Young, Yong Li, Zijun Y Xu-Monette, Jeremy S Abramson, Aliyah R Sohani, Govind Bhagat, Alexandar Tzankov, Chiara Rusconi, Shanxiang Zhang, Karen Dybkær, Zenggang Pan, Mina L Xu, Wayne Tam, Youli Zu, Eric D Hsi, Fredrick B Hagemeister, Heounjeong Go, J van Krieken, Jane N Winter, Maurilio Ponzoni, Andrés José Maria Ferreri, Michael Boe Møller, Miguel Angel Piris, Yingjun Wang, Mingzhi Zhang
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood advances (2022)
Jeremy S Abramson
Post-CAR relapse in DLBCL: a fork in the road. Blood 140 (24) (2022)
J Erika Haydu, Jenny S Maron, Robert A Redd, Kathleen M E Gallagher, Stephanie Fischinger, Jeffrey A Barnes, Ephraim P Hochberg, P Connor Connor Johnson, R W Takvorian, Katelin Katsis, Daneal Portman, Jade Ruiters, Sidney Sechio, Mary Devlin, Connor Regan, Kimberly G Blumenthal, Aleena Banerji, Allen D Judd, Krista J Scorsune, Brianne M McGree, Maryanne M Sherburne, Julia M Lynch, James I Weitzman, Matthew M Lei, Camille Nelson Kotton, Anand S Dighe, Marcela V Maus, Galit Alter, Jeremy S Abramson, Jacob D Soumerai
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood advances 6 (6) (2022)
Ann Steward LaCasce, Travis Dockter, Amy S Ruppert, Lale Kostakoglu, Heiko Schöder, Eric D Hsi, Jeffrey A Bogart, Bruce D Cheson, Nina Wagner-Johnston, Jeremy S Abramson, Kristie A Blum, John P Leonard, Nancy L Bartlett
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
J Erika Haydu, Jeremy S Abramson
CAR T-cells in relapsed Burkitt lymphoma - a promising test drive in a rare disease. Leukemia & lymphoma 63 (10) (2022)
Jacob D Soumerai, Allison Rosenthal, Shannon K Harkins, Jessica Duffy, Carmen Mecca, Yingbing Wang, Ravinder K Grewal, Areej R El-Jawahri, Huiyun Liu, Cedric Menard, Ahmet Dogan, Lei Yang, Lisa M Rimsza, Kurt Bantilan, Haley Martin, Matthew M Lei, Sydney Mohr, Anna Kurilovich, Olga Mikhaylovna Plotnikova, Ekaterina Postovalova, Valentina Nardi, Jeremy S Abramson, Roberto Chiarle, Andrew D Zelenetz, Abner Louissaint
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood 140 (16) (2022)
Jeremy S Abramson, Scott R Solomon, Jon E Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim G N J Mutsaers, Francisco J Hernandez-Ilizaliturri, Koji Izutsu, Judith Trotman, Matthew A Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood (2022)
Fallon E Chipidza, Mukendi K A Kayembe, Isaac Nkele, Jason Alexander Efstathiou, Bruce A Chabner, Jeremy S Abramson, Scott L Dryden-Peterson, Aliyah R Sohani
Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana. JCO global oncology 7 (2022)
Jeremy S Abramson, Elizabeth Bengtson, Robert A Redd, Jeffrey A Barnes, Tak Takvorian, Lubomir Sokol, Frederick Lansigan, Philippe Armand, Bijal D Shah, Eric D Jacobsen, Rosalba Martignetti, Elyce Turba, Sara Metzler, Victoria Patterson, Ann Steward LaCasce, Celeste M Bello
Brentuximab vedotin plus adriamycin and dacarbazine in nonbulky limited-stage Hodgkin lymphoma: results of a phase 2 trial. Blood advances (2022)
Kristie A Blum, Jeffrey G Supko, Michael B Maris, Ian W Flinn, Andre H Goy, Anas Younes, Suresh Bobba, Adrian M Senderowicz, Sergey Efuni, Ronda Rippley, Gozde Colak, Patrick Trojer, Jeremy S Abramson
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer research communications 2 (8) (2022)
Nicole Thomas, Kostiantyn Dreval, Daniela S Gerhard, Laura K Hilton, Jeremy S Abramson, Stefan K Barta, Nancy L Bartlett, Jeffrey Bethony, Kishor Bhatia, Jay Bowen, Anthony C Bryan, Ethel Cesarman, Corey Casper, Manuela Cruz, Maureen Dyer, Pedro Farinha, Julie Gastier-Foster, Alina S Gerrie, Bruno M Grande, Timothy C Greiner, Nicholas Griner, Thomas G Gross, Nancy Lee Harris, John D Irvin, Elaine S Jaffe, David Henry, Rebecca Liddell Huppi, Fabio E Leal, Michael Lee, Jean Paul Martin, Marie-Reine Martin, Sam M Mbulaiteye, Ronald Mitsuyasu, Vivian Morris, Charles G Mullighan, Andrew J Mungall, Karen Mungall, Innocent Mutyaba, Mostafa Nokta, Constance Namirembe, Ariela Noy, Martin David Ogwang, Abrahams Omoding, Jackson Orem, German Ott, Hilary Petrello, Stefania Pittaluga, James D Phelan, Juan Carlos Ramos, Lee Ratner, Steven J Reynolds, Paul G Rubinstein, Gerhard Sissolak, Graham W Slack, Shaghayegh Soudi, Steven Howard Swerdlow, Alexandra Traverse-Glehen, Wyndham Wilson, Jasper Chun Hei Wong, Robert Yarchoan, Jean C ZenKlusen, Marco A Marra, Louis M Staudt, David W Scott, Ryan D Morin
GENETIC SUBGROUPS INFORM ON PATHOBIOLOGY IN ADULT AND PEDIATRIC BURKITT LYMPHOMA. Blood (2022)
Jeremy S Abramson
Post-CAR relapse in DLBCL: a fork in the road. Blood 140 (24) (2022)
Jeremy S Abramson
Post-CAR relapse in DLBCL: a fork in the road. Blood 140 (24) (2022)
Martin Hutchings, John Radford, Stephen M Ansell, Árpád Illés, Anna Sureda, Joseph M Connors, Alice Sýkorová, Hirohiko Shibayama, Jeremy S Abramson, Neil S Chua, Jonathan W Friedberg, Jan Kořen, Ann Steward LaCasce, Lysiane Molina, Gerald Engley, Keenan Fenton, Hina Jolin, Rachael Liu, Ashish Gautam, Andrea Gallamini
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematological oncology 39 (2) (2021)
Eric Mou, Lorenzo Falchi, Vandana Sundaram, Jeremy S Abramson, Ronald Balassanian, Sara Beygi, Megan J Fitzpatrick, Annabel Kate Frank, Srishti Gupta, Oscar Lin, Joshua R Reed, Steven R Long, Amy Ly, Joshua R Menke, Daniel R Reed, Roberto Ruiz-Cordero, Ashley K Volaric, Yi Xie, Linlin Wang, Kwun Wah Wen, Sara L Zadeh, Yasodha Natkunam, Matthew C Cheung, Dita A Gratzinger, null null
Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation. Leukemia & lymphoma 62 (12) (2021)
Matthew M Lei, Aleksandra N Watson, Jeremy S Abramson
Evaluation of the impact of timing of pegfilgrastim administration on incidence of febrile neutropenia in elderly patients with B-cell non-Hodgkin lymphomas receiving R-CHOP-21. Leukemia & lymphoma 61 (12) (2020)
Giselle K Perez, Emily A Walsh, Kit Quain, Jeremy S Abramson, Elyse R Park
A virtual resiliency program for lymphoma survivors: helping survivors cope with post-treatment challenges. Psychology & health 36 (11) (2020)
Benjamin L Lampson, Haesook T Kim, Matthew S Davids, Jeremy S Abramson, Arnold S Freedman, Caron A Jacobson, Philippe A Armand, Robin M Joyce, Jon E Arnason, Laura Z Rassenti, Thomas J Kipps, Joshua Alexander Fein, Stacey M Fernandes, John R Hanna, David C Fisher, Jennifer R Brown
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood advances 3 (7) (2020)
P Connor Johnson, Jeremy S Abramson
Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas. Leukemia & lymphoma 61 (11) (2020)
Jeremy S Abramson
Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment? Cancer 125 (18) (2019)
Jeremy S Abramson, Jon E Arnason, Ann Steward LaCasce, Robert Redd, Jeffrey A Barnes, Lubomir Sokol, Robin M Joyce, David Avigan, Donna Neuberg, Ronald W Takvorian, Ephraim P Hochberg, Celeste M Bello
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood 134 (7) (2019)
Matthew J Frigault, Jorg Dietrich, Maria Martinez-Lage, Mark B Leick, Bryan D Choi, Zachariah DeFilipp, Yi-Bin Chen, Jeremy S Abramson, Jennifer Crombie, Philippe Armand, Lakshmi Nayak, Chris Panzini, Lauren S Riley, Kathleen Gallagher, Marcela V Maus
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 134 (11) (2019)
Jeremy S Abramson, Kelly E Irwin, Matthew J Frigault, Jorg Dietrich, Brianne McGree, Justin T Jordan, Andrew J Yee, Yi-Bin Chen, Noopur S Raje, Jeffrey A Barnes, Benjamin Davis
Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer 125 (21) (2019)